Literature DB >> 11600398

In vitro and in vivo activities of sitafloxacin against Chlamydia spp.

N Miyashita1, Y Niki, T Matsushima.   

Abstract

The in vitro and in vivo antichlamydial activity of sitafloxacin was investigated. The MICs and minimal chlamydiacidal concentrations of sitafloxacin for various species of chlamydia ranged from 0.031 to 0.125 microg/ml. Sitafloxacin had an excellent therapeutic effect on experimental Chlamydia psittaci pneumonia and was more potent than tosufloxacin, ofloxacin, and ciproflxacin, although slightly less potent than sparfloxacin.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11600398      PMCID： PMC90824          DOI： 10.1128/AAC.45.11.3270-3272.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Etiology of community-acquired pneumonia requiring hospitalization in Japan.

Authors:  N Miyashita; H Fukano; Y Niki; T Matsushima; N Okimoto
Journal:  Chest       Date:  2001-04       Impact factor: 9.410

2.  Microbiological efficacy of levofloxacin for treatment of community-acquired pneumonia due to Chlamydia pneumoniae.

Authors:  M R Hammerschlag; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.

Authors:  P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

4.  In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.

Authors:  N Miyashita; Y Niki; T Kishimoto; M Nakajima; T Matsushima
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

5.  In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.

Authors:  P M Roblin; G Montalban; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

Review 6.  Chlamydia pneumoniae (TWAR).

Authors:  C C Kuo; L A Jackson; L A Campbell; J T Grayston
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

7.  Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method.

Authors:  M Tanaka; K Hoshino; M Hohmura; H Ishida; A Kitamura; K Sato; I Hayakawa; T Nishino
Journal:  J Antimicrob Chemother       Date:  1996-06       Impact factor: 5.790

8.  Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.

Authors:  K Sato; K Hoshino; M Tanaka; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

9.  In vitro activities of five quinolones against Chlamydia pneumoniae.

Authors:  M R Hammerschlag; C L Hyman; P M Roblin
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

10.  In vitro antibacterial activity of DU-6859a, a new fluoroquinolone.

Authors:  T Nakane; S Iyobe; K Sato; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.